# Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

> **NCT01147640** · PHASE2 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 122 (actual)

## Conditions studied

- Complicated Intra-abdominal Infection

## Interventions

- **DRUG:** CXA-101/ tazobactam and metronidazole
- **DRUG:** meropenem plus saline placebo

## Key facts

- **NCT ID:** NCT01147640
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-25
- **Primary completion:** 2011-02-20
- **Final completion:** 2011-03-25
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147640, "Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01147640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*